Peripheral neuropathy in Parkinson's disease: Levodopa exposure and implications for duodenal delivery

Thomas Müller, Teus van Laar, David R. Cornblath, Per Odin, Fabian Klostermann, Francisco J. Grandas, Georg Ebersbach, Peter P. Urban, Francesc Valldeoriola, Angelo Antonini

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

In advanced Parkinson's disease (PD) patients, continuous intra-duodenal infusion of levodopa/carbidopa intestinal gel (LCIG) is an established approach in the management of motor complications that cannot be further improved by conventional oral therapy. In general, tolerability of LCIG has resembled that of oral dopaminergic therapy; however, cases of symptomatic peripheral neuropathy (PN), sometimes severe, have been reported in patients receiving LCIG. Cases are generally a sensorimotor polyneuropathy with both subacute and chronic onsets, often associated with vitamin B12 and/or B6 deficiency. Rare cases clinically resemble Guillain-Barré syndrome. In the absence of prospectively collected data on possible associations between LCIG and PN, it is prudent to explore potential mechanisms that may explain a possible relationship. The PN may be linked to use of high-dose levodopa, promoting high levels of homocysteine and methylmalonic acid or reduced absorption of vitamins essential for homocysteine metabolism. Cases of LCIG-associated PN often have responded to vitamin supplementation without need for LCIG cessation, although LCIG cessation is sometimes necessary. It may be advisable to monitor vitamin B12/B6 status before and after patients start LCIG and be vigilant for signs of PN. Prospective, large-scale, long-term studies are needed to clarify whether vitamin supplementation and routine use of a catechol-O-methyltransferase inhibitor may help prevent PN in LCIG recipients and whether these measures should be routine practice in patients with PD on high-dose oral levodopa.

Original languageEnglish
Pages (from-to)501-507
Number of pages7
JournalParkinsonism and Related Disorders
Volume19
Issue number5
DOIs
Publication statusPublished - May 2013

Fingerprint

Levodopa
Peripheral Nervous System Diseases
Parkinson Disease
Gels
Vitamins
Homocysteine
Methylmalonic Acid
Vitamin B 6 Deficiency
Vitamin B 12 Deficiency
levodopa drug combination carbidopa
Vitamin B 6
Polyneuropathies
Vitamin B 12
Therapeutics

Keywords

  • Homocysteine
  • Levodopa/carbidopa intestinal gel
  • Parkinson's disease
  • Peripheral neuropathy
  • Vitamin B

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Clinical Neurology
  • Neurology

Cite this

Müller, T., Laar, T. V., Cornblath, D. R., Odin, P., Klostermann, F., Grandas, F. J., ... Antonini, A. (2013). Peripheral neuropathy in Parkinson's disease: Levodopa exposure and implications for duodenal delivery. Parkinsonism and Related Disorders, 19(5), 501-507. https://doi.org/10.1016/j.parkreldis.2013.02.006

Peripheral neuropathy in Parkinson's disease : Levodopa exposure and implications for duodenal delivery. / Müller, Thomas; Laar, Teus van; Cornblath, David R.; Odin, Per; Klostermann, Fabian; Grandas, Francisco J.; Ebersbach, Georg; Urban, Peter P.; Valldeoriola, Francesc; Antonini, Angelo.

In: Parkinsonism and Related Disorders, Vol. 19, No. 5, 05.2013, p. 501-507.

Research output: Contribution to journalArticle

Müller, T, Laar, TV, Cornblath, DR, Odin, P, Klostermann, F, Grandas, FJ, Ebersbach, G, Urban, PP, Valldeoriola, F & Antonini, A 2013, 'Peripheral neuropathy in Parkinson's disease: Levodopa exposure and implications for duodenal delivery', Parkinsonism and Related Disorders, vol. 19, no. 5, pp. 501-507. https://doi.org/10.1016/j.parkreldis.2013.02.006
Müller, Thomas ; Laar, Teus van ; Cornblath, David R. ; Odin, Per ; Klostermann, Fabian ; Grandas, Francisco J. ; Ebersbach, Georg ; Urban, Peter P. ; Valldeoriola, Francesc ; Antonini, Angelo. / Peripheral neuropathy in Parkinson's disease : Levodopa exposure and implications for duodenal delivery. In: Parkinsonism and Related Disorders. 2013 ; Vol. 19, No. 5. pp. 501-507.
@article{85a45c717a63440c8bf3b7ae1fd696d4,
title = "Peripheral neuropathy in Parkinson's disease: Levodopa exposure and implications for duodenal delivery",
abstract = "In advanced Parkinson's disease (PD) patients, continuous intra-duodenal infusion of levodopa/carbidopa intestinal gel (LCIG) is an established approach in the management of motor complications that cannot be further improved by conventional oral therapy. In general, tolerability of LCIG has resembled that of oral dopaminergic therapy; however, cases of symptomatic peripheral neuropathy (PN), sometimes severe, have been reported in patients receiving LCIG. Cases are generally a sensorimotor polyneuropathy with both subacute and chronic onsets, often associated with vitamin B12 and/or B6 deficiency. Rare cases clinically resemble Guillain-Barr{\'e} syndrome. In the absence of prospectively collected data on possible associations between LCIG and PN, it is prudent to explore potential mechanisms that may explain a possible relationship. The PN may be linked to use of high-dose levodopa, promoting high levels of homocysteine and methylmalonic acid or reduced absorption of vitamins essential for homocysteine metabolism. Cases of LCIG-associated PN often have responded to vitamin supplementation without need for LCIG cessation, although LCIG cessation is sometimes necessary. It may be advisable to monitor vitamin B12/B6 status before and after patients start LCIG and be vigilant for signs of PN. Prospective, large-scale, long-term studies are needed to clarify whether vitamin supplementation and routine use of a catechol-O-methyltransferase inhibitor may help prevent PN in LCIG recipients and whether these measures should be routine practice in patients with PD on high-dose oral levodopa.",
keywords = "Homocysteine, Levodopa/carbidopa intestinal gel, Parkinson's disease, Peripheral neuropathy, Vitamin B",
author = "Thomas M{\"u}ller and Laar, {Teus van} and Cornblath, {David R.} and Per Odin and Fabian Klostermann and Grandas, {Francisco J.} and Georg Ebersbach and Urban, {Peter P.} and Francesc Valldeoriola and Angelo Antonini",
year = "2013",
month = "5",
doi = "10.1016/j.parkreldis.2013.02.006",
language = "English",
volume = "19",
pages = "501--507",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier BV",
number = "5",

}

TY - JOUR

T1 - Peripheral neuropathy in Parkinson's disease

T2 - Levodopa exposure and implications for duodenal delivery

AU - Müller, Thomas

AU - Laar, Teus van

AU - Cornblath, David R.

AU - Odin, Per

AU - Klostermann, Fabian

AU - Grandas, Francisco J.

AU - Ebersbach, Georg

AU - Urban, Peter P.

AU - Valldeoriola, Francesc

AU - Antonini, Angelo

PY - 2013/5

Y1 - 2013/5

N2 - In advanced Parkinson's disease (PD) patients, continuous intra-duodenal infusion of levodopa/carbidopa intestinal gel (LCIG) is an established approach in the management of motor complications that cannot be further improved by conventional oral therapy. In general, tolerability of LCIG has resembled that of oral dopaminergic therapy; however, cases of symptomatic peripheral neuropathy (PN), sometimes severe, have been reported in patients receiving LCIG. Cases are generally a sensorimotor polyneuropathy with both subacute and chronic onsets, often associated with vitamin B12 and/or B6 deficiency. Rare cases clinically resemble Guillain-Barré syndrome. In the absence of prospectively collected data on possible associations between LCIG and PN, it is prudent to explore potential mechanisms that may explain a possible relationship. The PN may be linked to use of high-dose levodopa, promoting high levels of homocysteine and methylmalonic acid or reduced absorption of vitamins essential for homocysteine metabolism. Cases of LCIG-associated PN often have responded to vitamin supplementation without need for LCIG cessation, although LCIG cessation is sometimes necessary. It may be advisable to monitor vitamin B12/B6 status before and after patients start LCIG and be vigilant for signs of PN. Prospective, large-scale, long-term studies are needed to clarify whether vitamin supplementation and routine use of a catechol-O-methyltransferase inhibitor may help prevent PN in LCIG recipients and whether these measures should be routine practice in patients with PD on high-dose oral levodopa.

AB - In advanced Parkinson's disease (PD) patients, continuous intra-duodenal infusion of levodopa/carbidopa intestinal gel (LCIG) is an established approach in the management of motor complications that cannot be further improved by conventional oral therapy. In general, tolerability of LCIG has resembled that of oral dopaminergic therapy; however, cases of symptomatic peripheral neuropathy (PN), sometimes severe, have been reported in patients receiving LCIG. Cases are generally a sensorimotor polyneuropathy with both subacute and chronic onsets, often associated with vitamin B12 and/or B6 deficiency. Rare cases clinically resemble Guillain-Barré syndrome. In the absence of prospectively collected data on possible associations between LCIG and PN, it is prudent to explore potential mechanisms that may explain a possible relationship. The PN may be linked to use of high-dose levodopa, promoting high levels of homocysteine and methylmalonic acid or reduced absorption of vitamins essential for homocysteine metabolism. Cases of LCIG-associated PN often have responded to vitamin supplementation without need for LCIG cessation, although LCIG cessation is sometimes necessary. It may be advisable to monitor vitamin B12/B6 status before and after patients start LCIG and be vigilant for signs of PN. Prospective, large-scale, long-term studies are needed to clarify whether vitamin supplementation and routine use of a catechol-O-methyltransferase inhibitor may help prevent PN in LCIG recipients and whether these measures should be routine practice in patients with PD on high-dose oral levodopa.

KW - Homocysteine

KW - Levodopa/carbidopa intestinal gel

KW - Parkinson's disease

KW - Peripheral neuropathy

KW - Vitamin B

UR - http://www.scopus.com/inward/record.url?scp=84875554066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875554066&partnerID=8YFLogxK

U2 - 10.1016/j.parkreldis.2013.02.006

DO - 10.1016/j.parkreldis.2013.02.006

M3 - Article

C2 - 23453891

AN - SCOPUS:84875554066

VL - 19

SP - 501

EP - 507

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

IS - 5

ER -